Allogene Therapeutics (NASDAQ:ALLO) Shares Up 9.6%

Allogene Therapeutics, Inc. (NASDAQ:ALLOGet Free Report)’s share price traded up 9.6% on Thursday . The company traded as high as $4.58 and last traded at $4.55. 879,968 shares changed hands during trading, a decline of 72% from the average session volume of 3,138,884 shares. The stock had previously closed at $4.15.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Citigroup assumed coverage on shares of Allogene Therapeutics in a research note on Friday, December 8th. They set a “buy” rating and a $7.00 target price on the stock. JMP Securities reissued a “market perform” rating on shares of Allogene Therapeutics in a research note on Friday, January 5th. HC Wainwright lowered their target price on shares of Allogene Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 19th. Finally, Guggenheim lowered shares of Allogene Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, January 5th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.29.

Read Our Latest Stock Analysis on Allogene Therapeutics

Allogene Therapeutics Stock Up 0.2 %

The stock’s fifty day simple moving average is $3.19 and its 200 day simple moving average is $3.39.

Insider Buying and Selling at Allogene Therapeutics

In other Allogene Therapeutics news, Director Deborah M. Messemer sold 18,640 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $2.70, for a total value of $50,328.00. Following the completion of the sale, the director now owns 62,456 shares in the company, valued at approximately $168,631.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 27.40% of the stock is owned by insiders.

Institutional Trading of Allogene Therapeutics

A number of hedge funds have recently bought and sold shares of ALLO. Oppenheimer & Co. Inc. increased its holdings in Allogene Therapeutics by 24.9% in the 1st quarter. Oppenheimer & Co. Inc. now owns 15,050 shares of the company’s stock valued at $137,000 after purchasing an additional 3,000 shares during the last quarter. AlphaCrest Capital Management LLC lifted its position in shares of Allogene Therapeutics by 83.4% during the 1st quarter. AlphaCrest Capital Management LLC now owns 49,574 shares of the company’s stock worth $452,000 after purchasing an additional 22,540 shares during the last quarter. MetLife Investment Management LLC lifted its position in shares of Allogene Therapeutics by 58.6% during the 1st quarter. MetLife Investment Management LLC now owns 36,326 shares of the company’s stock worth $331,000 after purchasing an additional 13,419 shares during the last quarter. BlackRock Inc. lifted its position in shares of Allogene Therapeutics by 8.6% during the 1st quarter. BlackRock Inc. now owns 7,086,233 shares of the company’s stock worth $64,557,000 after purchasing an additional 560,279 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Allogene Therapeutics by 8.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 805,987 shares of the company’s stock worth $7,344,000 after purchasing an additional 61,259 shares during the last quarter. Institutional investors and hedge funds own 78.51% of the company’s stock.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

Further Reading

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.